Withdrawal of inhaled corticosteroids is known to worsen disease control in bronchial asthma but similar data are lacking in chronic obstructive pulmonary disease (COPD). We hypothesized that clinical exacerbations requiring treatment would occur more often in patients whose inhaled corticosteroids were stopped than in other patients not treated with these agents. We studied 272 patients of mean age 65 (SD 0.8) years, mean FEV, 42.8 (SD 12.6)% predicted, entering the run-in phase of the Inhaled Steroids in Obstructive Lung Disease (ISOLDE) trial. All had been clinically stable for at least 6 weeks and there were no differences in the degree of bronchodilator reversibility, baseline lung function or pack-years of smoking between the 160 patients receiving inhaled corticosteroids and those not so treated. Inhaled corticosteroids were withdrawn in the first week of the study and during the remaining 7 weeks of the study 38% of those previously treated with these drugs had an exacerbation compared to 6% of the chronically untreated group. Patients receiving inhaled corticosteroids reported a longer duration of symptoms but neither this or any other recorded variable predicted the risk of exacerbation. These data suggest that abrupt withdrawal of inhaled corticosteroids should be monitored carefully even in patients with apparently irreversible COPD.
Introduction
Inhaled corticosteroids are recognized as being the cornerstone of the management of chronic bronchial asthma (1, 2) . Placebo-controlled trials in stable asthma have shown that the FEV,, symptom scores and bronchial reactivity all improve significantly with regular inhaled corticosteroid treatment (3) . Conversely, withdrawal of oral corticosteroids in unstable asthma (4) and even in stable asthma will produce symptomatic and objective relapse at variable times after treatment cessation (S-7).
The position in chronic obstructive pulmonary disease (COPD) is much less certain. Short courses of oral corticosteroids can produce significant increases in FEV, in approximately 20% of patients with COPD (g- 10) . One open long-term follow-up study has suggested that mor-."_. . tality in COPD is reduced in those patients showing an initial improvement in spirometry after oral corticosteroids (11). Inhaled beclomethasone in moderate to high dosage can produce similar short-term effects to oral prednisolone (12) whilst other studies suggest that these improvements can be sustained with regular therapy (13, 14) . However there are no data about the effect of inhaled corticosteroid withdrawal in COPD patients. All the studies described above have limitations of design and/or statistical power. To resolve these problems, two prospective studies of inhaled corticosteroids in COPD, EUROSCOP (15) and ISOLDE (16) , have been established and are due to report soon. The Inhaled Steroids in Obstructive Lung Disease (ISOLDE) study is a multi-centre investigation based in the U.K. where the empirical use of inhaled corticosteroids in COPD is widespread. Patients already established on this treatment can enter the study if they are shown to be stable off corticosteroid therapy. We hypothesized that a percentage of the patients who had received inhaled corticosteroids would have benefited from this chronic anti-inflammatory treatment and would show an increased exacerbation rate when it was withdrawn. The run-in phase of ISOLDE allowed us to observe whether this was the case and determine whether there were any simple factors which id&&ed patients likely to deteriorate.
Methods
Patients were recruited for this study from the hospital outpatient departments and affiliated general practices of six of the centres participating within the ISOLDE trial. Each patient had a clinical history of COPD (17) , was aged between 40 and 75 years and had evidence of significant airflow obstruction with an FEV, greater than 0.8 1 but less than 70% of predicted values 30 min after receiving 400 mcg salbutamol from a metered dose inhaler via a volumatic spacer. Their FEV,/FVC ratio was less than 75% and none showed more than a 10% of predicted FEV, improvement from baseline after the inhaled salbutamol. Patients with concurrent life-threatening illnesses or clinical features suggestive of bronchial asthma or a previous physician diagnosis of asthma were excluded and all had been clinically stable for at least 3 months before entry. All patients were receiving symptomatic bronchodilator treatment with p-agonists or anticholinergics and those receiving methylxanthines were allowed to continue these drugs. Patients taking regular oral prednisolone were not eligible, although treatment with oral prednisolone for acute exacerbations in the preceding year did not exclude entry. Informed consent for the study was obtained from all patients and the study protocol was approved by the local ethical committees of the participating centres prior to the study.
Patients attended on three occasions. At the first visit they completed an MRC respiratory questionnaire (18) from which demographic details, disease duration and the smoking history were extracted. Smoking exposure was expressed as pack years with 20 g of tobacco being considered equivalent to 1 packet of commercial cigarettes in those who used hand-rolled tobacco. Spirometry was performed using a computerized rolling seal spirometer (Sensormedics type 922, Amsterdam) the patient being instructed not to take any oral or inhaled bronchodilators for 6 h before the study. The FEV, and FVC were recorded from the three best traces which were within 10% of each other, particular care being taken to ensure the reproducibility of the FEV, and FVC manoeuvres (19) . After the initial spirometry patients were given 400 mcg salbutamol by metered dose inhaler through a volumatic spacer and the spirometry was repeated 30 min later. Reversibility was expressed according to the equation: FEV, post salbutamol -FEV, pre-salbutamol/predicted FEV, x 100. The predicted values were those of the European Coal and Steel Community (ECSC) (20) . Patients were considered eligible if the change in FEV, after bronchodilator was less than 10% of their predicted baseline FEV,. The transfer factor for carbon monoxide (2X0) and the transfer coefficients (KCO) were measured using the single breath method in all patients. Plasma cortisols were taken between 0800h and lOOOh to seek evidence of prior adrenal suppression whilst plasma IgE and eosinophil counts were taken as potential markers of allergic status. A history of the inhaled and oral corticosteroid exposure during the previous history was also obtained.
Those patients who had received inhaled corticosteroids were told to withdraw these at their own discretion during the next 7 days and given an appointment to return. Patients were reviewed at 4 and 8 weeks after the initial visit for evidence of clinical stability. Our predefined definition of an exacerbation of COPD was an episode of 'increased shortness of breath and/or sputum production requiring treatment with antibiotics and/or prednisolone'. Where treatment was required it was instituted by a hospital physician familiar with the study protocol or, less frequently, by the patient's own general practitioner.
Data are expressed as mean (SD) unless otherwise stated. The chi-squared test was used to compare frequencies of exacerbations and duration of disease, and the Student's t-test for continuous data with a normal distribution (age, plasma cortisol and serum IgE).
The Mann-Whitney U-test was used where data were not normally distributed (pack-years cigarette smoking and the dose of inhaled and oral steroids). Due to the multiple comparisons performed in the study the value of P was corrected using the equation described by Bonferroni (21):
where k is the number of analyses undertaken (26 analyses in this study). The results were considered significant if P,,,, was less than 0.05.
Results
All patients entering the run-in from the six participating centres were included; a total of 272 patients. Most were men (72%) with a mean FEV, of 42.1 (12+)% predicted and limited bronchodilator reversibility (4.2% predicted increase from baseline) compatible with COPD. There were no inter-centre differences in the baseline characteristics of the patients.
PATIENTS CHARACTERIZED BY TREATMENT AT STUDY ENTRY
One hundred and sixty patients (59%) were receiving regular inhaled corticosteroids (Group 1) (median daily dose 800 mcg, range 50-2400) as either beclomethosone dipropionate or budesonide when enrolled. These are compared to the remaining 112 patients (Group 2) in Table 1 . There were no significant differences in any characteristics save that patients receiving inhaled corticosteroids (Group 1) reported a longer duration of symptoms than those not so treated (Group 2) (odds ratio 3.13, 95% CI 1.84-5.32;
PCO.001).
PRIOR ORAL CORTICOSTEROID USE Seventy-six patients had had at least one exacerbation requiring oral corticosteroids in the year before study entry. Of these 56 were receiving inhaled corticosteroids, i.e. 35% 
FOLLOW-UP
Sixty-seven (25%) patients had at least one exacerbation of COPD requiring treatment during the g-week study period (Table 2 ). In 55 (82%) the exacerbation occurred during the 1st month of observation (median 20 days). Ninety per cent of patients with an exacerbation had received inhaled corticosteroids previously, compared with 48% of those not exacerbating (odds ratio 9.5, 95% CI 4.0-23.3, P<O.OOl).
Although the daily dose of inhaled corticosteroids in the year before study was greater in the corticosteroid-treated patients who had an exacerbation (mean 945, median 800 mcg day-') compared with similar patients who did not (mean 712, median 534) these difference were not statistically significant. There was no correlation between the total dose of inhaled or oral corticosteroids used in the year before study and the time between stopping the corticosteroids in the first exacerbation. There were no differences in the baseline characteristics listed above, nor in markers of a potential asthmatic tendency between patients who had received inhaled corticosteroids and exacerbated and those who did not.
Discussion
Chronic obstructive pulmonary disease is an important cause of mortality and morbidity in the U.K. and elsewhere throughout Europe (22) . There is increasing evidence that airway inflammation is a frequent finding in COPD (23), perhaps associated with a different pattern of lymphocyte activation than in asthma (24) , and can respond physiologically to oral corticosteroids, especially when the eosinophil cationic protein (ECP) levels in bronchoalveolar lavage are high (25) . Regular treatment with inhaled corticosteroids may modify the rate of decline of pre-bronchodilator FEV, (14) but they have less impressive effects than lung function decline in mild disease when patients continue to smoke, as suggested by preliminary analysis of the EUROSCOP data. This is the first report to observe that withdrawal of inhaled corticosteroids leads to a clinically significant deterioration more often than would be expected among clinically and physiologically similar patients who have not received this treatment.
The trial design we have used has a number of limitations. The principal purpose of the ISOLDE study is to demonstrate in a double-blind placebo-controlled fashion that regular treatment with inhaled fluticasone propionate reduces the rate of decline in lung function and improves the quality of life of patients with stable COPD. To draw this conclusion it is important that the baseline value of lung function be representative of the patient's usual value.
For the purpose of this report it would have been better to randomize patients to treatment with active or placebo inhaled corticosteroids and our inability to do so restricts the conclusions we can draw. However, recruitment for such a large multi-centre study is difficult and the inclusion of a protracted run-in period might have compromised the main purpose of the study. Since this is the first large scale COPD study in which patients had their prior inhaled steroids withdrawn we felt that the large number of subjects involved would go some way to compensate for some of these design difficulties. The investigators who collected the data and the patients themselves were unaware of the hypothesis being tested or the reasons for the additional data being collected. Thus we think it unlikely that the differences between the two groups arose by chance. It is possible that patients used to receiving inhaled corticosteroids might be more anxious when they were withdrawn but the ,great majority of patients in this study, and in our clinical practice, do not attribute specific benefits to using their inhaled corticosteroids and, if anything, are more concerned about the possibility of side-effects, making this placebo response unlikely.
There is no universally agreed definition of an exacerbation of COPD and the role of bacterial infection is unclear and often difficult to establish (26) . In the U.K. prescription of oral corticosteroids is reversed for clinically more severe episodes associated with breathlessness. Thus, we felt that institution of a course of corticosteroids was likely to represent a clinically significant event. Data about the occurrence of exacerbations of COPD are remarkably scarce (27) but two recent studies give some insight into this. In one a group of moderate to severe COPD patients (mean FEV, 1.6 l), most of whom received inhaled corticosteroids, reported an average of 1.5 exacerbations per year, although an equivalent number of unreported episodes occur (28) . In the second, 139 patients (mean FEV, 1.52 1) with a past history of exacerbations experience 111 exacerbations in 6 months, an annual rate of 1.6 episodes per year (29) . Assuming an equivalent rate in our patients, one-quarter of those stopping inhaled corticosteroids might experience exacerbation, whilst one-third did so. The low rate in those not receiving corticosteroids may be a chance occurrence and would require a longer follow-up period to explain.
Treatment of exacerbations before entry was not standardized and we would have liked information about the number of exacerbations treated by antibiotics alone. There were more individuals treated with oral corticosteroids in the preceding year among Group 1 patients, but those who had exacerbated in Group 2 before study entry had required oral therapy more often or for longer. Thus, the chances of an exacerbation occurring in a given group were broadly equivalent.
Although not the ideal control population, the patients who had not received inhaled corticosteroids appeared to be physiologically identical and to have similar degrees of reduction in their KCO. There were no differences in other medication between the groups and all of the patients had been stable on their previous medication for at least 3 months.
Given the original homogeneity of the population we believe that the difference in exacerbation rates is probably due to corticosteroid withdrawal, even allowing for the limitations of our study design. It is possible that the Group 1 patients included a large number of 'hidden asthmatics', but this seems unlikely given the high tobacco intake, the very limited bronchodilator response and the paucity of allergic markers.
We could not predict which patients would subsequently exacerbate. Similarly, when similar patients were studied previously no combination of clinical or laboratory features predicted a bronchodilator response to a trial of oral corticosteroids (10) . Data such as these suggest that the initial clinical picture is a poor guide to either the benefits of corticosteroid treatment or the risk of relapse on their withdrawal. In this study we have used exacerbations of COPD as our principal endpoint and although there is no widely accepted definition, the one used proved to be easy to apply in the clinical setting and is similar to that employed in longer-term studies of inhaled corticosteroids in asthma (30) . Its sensitivity in detecting clinically significant changes in these patients makes us believe that it should be incorporated as an appropriate study end-point in future investigations.
The reason for these exacerbations among the corticosteroid-using patients is still unclear. It seems unlikely that the initial clinical assessment was so precise as to pick out those patients showing a corticosteroid response compared with those who do not (see above). Given the recent information about inflammatory changes in the airways of COPD patients it seems possible that chronic suppression of lymphocytes and eosinophils by inhaled corticosteroids might lead to a rebound increase in these cells when the treatment was withdrawn and that this may help precipitate an increase in symptoms requiring treatment. Previous studies have suggested that sputum eosinophilia is a potential marker for a favourable corticosteroid response in COPD, whilst acute eosinophilia occurs during inflammatory exacerbations of mild to moderate COPD as demonstrated on biopsy studies (31) . This explanation must remain speculative until more direct evidence is obtained of the effects of corticosteroids on the histology of the airways in COPD and its relationship, if any, to their effects on the natural history of the disease.
These data do have practical implications. Our findings cannot give insight into whether long-term inhaled corticosteroids confer benefit. However, many research protocols involve the reduction or stopping of medications before study entry. Our data suggest that this may lead to early exacerbation if inhaled corticosteroids are rapidly withdrawn in stable COPD. Similarly, the controversy about the clinical role of inhaled corticosteroids in COPD means that different physicians may offer differing advice to patients about whether they should continue their therapy and the patients themselves may decide to discontinue treatment which is not giving them immediate benefit. Given the limitations of our study design, further randomized studies will be needed to confirm our findings and define the most appropriate way to stop inhaled corticosteroid treatment in COPD. In the meantime, clinicians should be aware of the risk of an exacerbation developing within a few weeks of stopping this treatment.
